Skip to content

Gastroesophageal Reflux Disease and Probiotics

Gastroesophageal Reflux Disease and Probiotics - GERD and Probiotics

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
LBCTR
Registry ID
LBCTR2023105464
Enrollment
400
Registered
2023-11-21
Start date
2023-11-15
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux Disease GERD

Interventions

Probiotics
Multi-strain probiotic, that contains Lactobacillus rhamnosus GG, Saccharomyces boulardii, Bifidobacterium breve, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacil
Probiotic

Sponsors

Lebanese American University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: • Patients with mild to moderate GERD symptoms (diagnosed on basis of clinical presentation) • Patients with GERD regardless of prior treatment for GERD but not currently on PPIs over at least 4 weeks

Exclusion criteria

Exclusion criteria: • Patients less than 18 years or above the age of 50 • Prior bariatric surgery • Epigastric mass • Prior endoscopy showing severe erosive esophagitis LA-C or LA-D • Alarm symptoms: weight loss, anemia, dysphagia or odynophagia, family history of malignancy, melena, hematemesis, nausea and vomiting • Pregnant women • Malignancy, IBD, immunosuppressive therapy • Advanced cardiac disease • Chronic uninterrupted use of PPI • ESRD • Use of probiotics within the last 6 months

Design outcomes

Primary

MeasureTime frame
Name: Gastroesophageal Reflux Disease Symptoms;Timepoints: 8 weeks;Measure: The Gastroesophageal Reflux Disease-Health Related Quality of Life instrument

Countries

Lebanon

Contacts

Public ContactOmar El Masri

Lebanese American University

omar.elmasri@lau.edu71354271

Outcome results

None listed

Source: LBCTR (via WHO ICTRP) · Data processed: Feb 7, 2026